ProCE Banner Activity

Phase III KEYNOTE-240: Second-line Treatment With Pembrolizumab + BSC vs Placebo + BSC in Advanced Hepatocellular Carcinoma

Slideset Download
Conference Coverage
In KEYNOTE-240, pembrolizumab showed nonsignificant improvement in PFS and OS compared with placebo as second-line therapy in advanced HCC.

Released: June 04, 2019

Expiration: June 02, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro